Lupus & antiphospholipid syndrome
Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort
Authors' conclusion
MC is a useful therapy in mild-moderate active SLE.
Study context
- Population
- Patients with SLE unresponsive to hydroxychloroquine (HCQ)-containing regimens, Lupus-Cruces cohort; all on HCQ and prednisone at baseline
- Participants
- 106 episodes
- Exposure
- Mepacrine (MC) add-on to single therapy vs multiple therapy
- Single therapy (ST)n = 56
- Multiple therapy (MT)n = 50reference
- Outcome
- DORIS remission
- Follow-up
- 6 months
Methodological detailsroutine clinical care data, logistic regression
- Routine clinical care data
- Logistic regression
Main finding
As reported in the abstract
P = 0.06
- Definition of remission in SLE (DORIS) remission, complete cohort
- 71%
Observational data: associations, not effects.
Further findings
| Outcome | ST | MT | P value |
|---|---|---|---|
| SLEDAI reduction (similar in both groups) · 6 monthsMean, points | 4.6 | 5 | P = 0.5 |
| Prednisone dose reduction (similar) · 6 monthsMean, mg/day | 1.75 | 1.69 | P = 0.9 |
Most frequent reason for MC discontinuation
- Improvement
- 45%
Safety
- Patients with adverse effects
- 17%
Original publication
Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort. Lupus Sci Med. Published 23 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →